With 0.18 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.2 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $18.42 whereas the lowest price it dropped to was $17.37. The 52-week range on AVBP shows that it touched its highest point at $36.37 and its lowest point at $14.35 during that stretch. It currently has a 1-year price target of $39.29. Beta for the stock currently stands at 1.41.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AVBP was up-trending over the past week, with a rise of 7.59%, but this was down by -7.45% over a month. Three-month performance dropped to -25.90% while six-month performance fell -36.15%. The stock gained 7.98% in the past year, while it has lost -31.91% so far this year. A look at the trailing 12-month EPS for AVBP yields -2.40 with Next year EPS estimates of -3.52. For the next quarter, that number is -0.66. This implies an EPS growth rate of -14.25% for this year and -20.47% for next year.
Float and Shares Shorts:
At present, 33.71 million AVBP shares are outstanding with a float of 19.43 million shares on hand for trading. On 2025-03-31, short shares totaled 4.07 million, which was 1197.0 higher than short shares on 1740700800. In addition to Dr. Zhengbin Yao Ph.D. as the firm’s Co-Founder, Chairman, President & CEO, Dr. Stuart Lutzker M.D., Ph.D. serves as its Co-Founder, President of Research & Development and Director.
Institutional Ownership:
Through their ownership of 0.84594 of AVBP’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, AVBP reported revenue of $0.0 and operating income of -$23705000.0. The EBITDA in the recently reported quarter was -$23705000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AVBP since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AVBP analysts setting a high price target of 45.0 and a low target of 36.0, the average target price over the next 12 months is 39.28571. Based on these targets, AVBP could surge 148.07% to reach the target high and rise by 98.46% to reach the target low. Reaching the average price target will result in a growth of 116.57% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.51446 being high and -$2.73106 being low. For AVBP, this leads to a yearly average estimate of -$2.58038.
